News
TAK
17.78
-0.39%
-0.07
Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors
TipRanks · 16h ago
Takeda’s Real-World Dengue Vaccine Study Could Reshape Its Emerging Markets Outlook
TipRanks · 16h ago
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
TipRanks · 3d ago
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Seeking Alpha · 3d ago
Spyre's inflammatory bowel drug reduces disease activity in mid-stage study
Reuters · 3d ago
Weekly Report: what happened at TAK last week (0406-0410)?
Weekly Report · 3d ago
Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push
TipRanks · 6d ago
Takeda upgraded to Outperform from Market Perform at Bernstein
TipRanks · 04/08 13:50
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Benzinga · 04/06 17:26
BUZZ-Denali slips as Takeda exits dementia drug partnership
Reuters · 04/06 15:57
Takeda files Form 3 for Chief Human Resources Officer Nicola Greenway
Reuters · 04/06 10:21
Takeda files initial beneficial ownership statement for Chief Medical Officer Awny Farajallah
Reuters · 04/06 10:19
Takeda files Form 3 for President, PDT BU Ramy Ibrahim
Reuters · 04/06 10:17
Weekly Report: what happened at TAK last week (0330-0403)?
Weekly Report · 04/06 09:15
Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026
Benzinga · 04/06 07:03
Denali Therapeutics regains full rights to DNL593
TipRanks · 04/06 01:15
Takeda Ends Denali Therapeutics Dementia-Drug Partnership
Dow Jones · 04/03 17:49
Denali regains full rights to DNL593 after Takeda ends collaboration
Reuters · 04/03 17:35
DENALI THERAPEUTICS INC - RESULTS FROM PHASE 1/2 STUDY IN FTD-GRN EXPECTED BY END OF 2026
Reuters · 04/03 17:30
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
NASDAQ · 04/03 09:10
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.